A new study by researchers at the University of Maryland School of Medicine (UMSOM; Baltimore, USA) found that patients with an abdominal aortic aneurysm (AAA) received no benefits from taking a common antibiotic drug to reduce inflammation.
LimFlow SA today announced publication of positive two-year data from the ALPS registry of the LimFlow percutaneous deep vein arterialisation (pDVA) system. Results were published online yesterday in the Journal of Endovascular Therapy and will also appear in the August print issue of the journal.
A study published in Circulation: Cardiovascular Interventions shows that robotic percutaneous coronary intervention with the CorPath GRX system (Corindus Vascular Robotics, Siemens Healthineers) reduces patient exposure to radiation by 20% compared to manual PCI with no increase in fluoroscopy time or contrast use.
Terumo Aortic today announced that the US Food and Drug Administration (FDA) has granted breakthrough device designation for its Thoraflex Hybrid stented device for complex aortic arch repair.
Mardil Medical has announced the successful completion of treatment for the third patient in the clinical trial of its improved VenTouch device for type IIIb functional mitral valve regurgitation. A press release reports that the device is a combination therapy which simultaneously treats the distorted valve, the dilated ventricle and the displaced papillary muscles. It adds that VenTouch is a minimally invasive surgical treatment for a condition associated with accelerated heart failure.
Sebastian Debus (University Heart Center, Hamburg-Eppendorf, Germany) is joined by Birgitta Sigvant (Uppsala University, Uppsala, Sweden) and Rupert Bauersachs (Clinic Darmstadt, Darmstadt, Germany) for a special ESVS Educational Webinar: “From Science to Practice: Impact of the VOYAGER PAD trial on interventions for PAD [peripheral arterial disease].”
Simon Ray, president of the British Cardiovascular Society (BCS), has told the COVID-19 Cardiovascular Conference that a lack of consistency in national guidance around personal protective equipment (PPE) during COVID-19 had led to a “vacuum” which has had to be filled by individual societies and membership organisations. This, he said, has created “a piecemeal approach, which does not necessarily join up”.
The longest follow-up to date of patients with left main coronary artery disease (LMCAD) has found no significant differences in rates of death, myocardial infarction or stroke between patients who underwent percutaneous coronary intervention (PCI) and those who had coronary artery bypass graft (CABG) surgery.
In stable atherosclerosis, a combination of aspirin plus rivaroxaban provided a similar relative degree of benefit on coronary, cerebrovascular, and peripheral endpoints in patients with and without diabetes, a prespecified analysis of the COMPASS trial has shown. It also noted that, given their higher baseline risk, the absolute benefits appeared greater in those with diabetes, including a three-fold greater reduction in all-cause mortality.
Treatment with aspirin plus rivaroxaban following lower extremity revascularisation in patients with peripheral arterial disease (PAD) leads to a 15% reduction in the risk of major adverse limb and cardiovascular events when compared with aspirin alone.
A viewpoint in the Journal of the American Medical Association has offered potential solutions to modifying ongoing randomised clinical trials during the COVID-19 pandemic. It aims to “minimise disruption and preserve integrity”, while still ensuring participant health and safety.
Performance diagnostique de l’interféron gamma dans l’identification de l’origine tuberculeuse des pleurésies exsudatives
A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease.
Radiological Approach to Asthma and COPD-The Role of Computed Tomography.
Significant annual cost savings found with UrgoStart in UK and Germany
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389